



Itw

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Donald J. Davidson, *et al.*

Serial No.: 10/753,646

Filed: January 8, 2004

For: NOVEL ANTIANGIOGENIC
PEPTIDES, POLYPEPTIDES
ENCODING SAME AND
METHODS FOR INHIBITING
ANGIOGENESIS

Examiner: (not assigned)

Group Art Unit: 1652

Case No.: 5940.US.C3

CERTIFICATE OF MAILING (37 CFR
1.8 (a))

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the:

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450, on:

Date of Deposit: September 27, 2004

 9/27/04
Kathleen Boettcher Date

TRANSMITTAL LETTER

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:


Enclosed herewith is an Information Disclosure Statement for Donald J. Davidson, *et al.* for, NOVEL ANTIANGIOGENIC PEPTIDES, POLYPEPTIDES ENCODING SAME AND METHODS FOR INHIBITING ANGIOGENESIS, the specification of which was filed on January 8, 2004, and received Serial No. 10/753,646.

Also enclosed are: Form PTO 1449 (in duplicate)
Return-receipt postcard

The Commissioner is hereby authorized to charge any additional Filing Fees required under 37 CFR 1.16, as well as any patent application processing fees under 37 CFR 1.17 associated with this communication for which full payment has not been tendered, to Deposit Account No. 01-0025. A duplicate copy of this sheet is enclosed.

Respectfully submitted,
Donald J. Davidson, *et al.*

ABBOTT LABORATORIES
Customer Number: 23492
Telephone: (847) 938-3137
Facsimile: (847) 938-2623


Dianne Casuto
Registration No. 40,943
Attorney for Applicants



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Donald J. Davidson, *et al.*

Serial No.: 10/753,646

Filed: January 8, 2004

For: NOVEL ANTIANGIOGENIC
PEPTIDES, POLYPEPTIDES
ENCODING SAME AND
METHODS FOR INHIBITING
ANGIOGENESIS

Examiner: (not assigned)

Group Art Unit: 1652

Case No.: 5940.US.C3

**CERTIFICATE OF MAILING (37 CFR
1.8 (a))**

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the:

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450, on:

Date of Deposit: September 27, 2004

Kathleen Boettcher 9/27/04
Kathleen Boettcher Date

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

This Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits under 37 CFR § 1.97(b).

Applicants submit herewith Form PTO 1449 listing the references cited in this Information Disclosure Statement. Applicants respectfully request that the Examiner (1) initial each reference listed on the enclosed Form PTO 1449 indicating that the Examiner has considered and made those references of record in this application and (2) return a copy of the initialed Form PTO 1449 to Applicants. Copies of the cited references have been previously submitted in U.S. Patent Application Serial No. 08/851,350, filed May 5, 1997. The aforementioned earlier application is relied on for an earlier, patent application filing date under 35 U.S.C. 120.

No charge is required for the submission of this Information Disclosure Statement under 37 C.F.R. § 1.97 (b). The Commissioner is hereby authorized to charge any additional filing fees required under 37 C.F.R. § 1.17 concerning this transmission, or to credit any overpayment to Deposit Account No. 01-0025.

ABBOTT LABORATORIES
Customer Number: 23492
Telephone: (847) 938-3137
Facsimile: (847) 938-2623

Respectfully submitted,
Donald J. Davidson, *et al.*

Dianne Casuto
Dianne Casuto
Registration No. 40,943
Attorney for Applicants

DATE: September 27, 2004 SHEET 1 of 2

Form PTO-1449 (Modified)

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE
(Modified) PATENT AND TRADEMARK OFFICEINFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use several sheets if necessary)

(37 CFR 1.98 (b))

ATTY. DOCKET NO.

5940.US.C3

SERIAL NO.

10/753,646

APPLICANT

D. J. Davidson, *et al.*

FILING DATE

January 8, 2004

GROUP

U.S. PATENT DOCUMENTS

| EXAMINER INITIAL | | PATENT NUMBER | | | | | | | ISSUE DATE | PATENTEE | CLASS | SUB CLASS | FILING DATE |
|---------------------|----|---------------|---|---|---|---|---|---|---------------|-------------------------|-------|--------------|----------------|
| | A1 | 5 | 4 | 0 | 7 | 6 | 7 | 3 | 04/1995 | Reich, <i>et al.</i> | | | |
| | A2 | 5 | 5 | 1 | 2 | 5 | 9 | 1 | 04/1996 | Halperin, <i>et al.</i> | | | |
| | A3 | 5 | 8 | 5 | 4 | 2 | 2 | 1 | 12/1998 | Cao, <i>et al.</i> | | | |

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

| | | DOCUMENT NUMBER | | | | | | | PUBLIC- ATION DATE | COUNTRY OR PATENT OFFICE | CLASS | SUB CLASS | TRANS- LATION | |
|--|----|-----------------|---|---|---|---|---|---|--------------------------|-----------------------------|-------|--------------|------------------|----|
| | | | | | | | | | | | | | YES | NO |
| | B1 | 9 | 2 | 0 | 4 | 4 | 5 | 0 | 19.03.92 | WO | | | | |
| | B2 | 9 | 5 | 2 | 9 | 2 | 4 | 2 | 02.11.95 | WO | | | | |
| | B3 | 9 | 7 | 2 | 3 | 5 | 0 | 0 | 02.1997 | WO | | | | |

OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)

| | | |
|--|-----|---|
| | C1 | SCRIP 2120:21 (4/16/96) |
| | C2 | Fidler, I.J., <i>et al.</i> , "The Implications of Angiogenesis for the Biology and Therapy of Cancer Metastasis", <i>Cell</i> , 79:185-188 (1994) |
| | C3 | Folkman, J., "Clinical Applications of Research on Angiogenesis", <i>The New England Journal of Medicine</i> , 333(26):1757-1763 (1995) |
| | C4 | Folkman, J., <i>et al.</i> , "Angiogenesis", <i>Jour. of Biological Chemistry</i> , 267(16):10931-10934 (1992) |
| | C5 | Folkman, J., <i>et al.</i> , "Angiogenic Factors", <i>Science</i> , 235:442-447 (1987) |
| | C6 | Gasparini, G., <i>et al.</i> , "Clinical Importance of the Determination of Tumor Angiogenesis in Breast Carcinoma: Much More Than a New Prognostic Tool", <i>Jour. of Clinical Oncology</i> , 13(3):765-782 (1995) |
| | C7 | Sottrup-Jensen, L., <i>et al.</i> , "The Primary Structure of Human Plasminogen: Isolation of Two Lysine-Binding Fragments and One "Mini-" Plasminogen (MW, 38,000) by Elastase-Catalyzed-Specific Limited Proteolysis", <i>Progress in Chemical Fibrinolysis and Thrombolysis</i> , 3:191-209 (1978) |
| | C8 | Kolberg, R., "Angogenic Inhibitor Loss May Be Key To Post-Surgery Metastasis", <i>Journal of NIH Research</i> , 8:31-33 (1994) |
| | C9 | McCance S., <i>et al.</i> , "Amino acid residues of the Kringle-4 and Kringle-5 domains of human plasminogen that stabilize their interactions with omega-amino acid ligands", <i>Journal of Biological Chemistry</i> , 269:32405-32410 (1994) |
| | C10 | Menhart, N., <i>et al.</i> , "Functional Independence of the Kringle 4 and Kringle 5 Regions of Human Plasminogen", <i>Biochemistry</i> , 32:8799-8806 (1993) |
| | C11 | Novokhatny, V. V., <i>et al.</i> , "Domains in Human Plasminogen", <i>J. Mol. Biol.</i> , 179:215-232 (1984) |
| | C12 | O'Reilly, M. S., <i>et al.</i> , "Angiostatin: A Novel Angiogenesis Inhibitor That Mediates the Suppression of Metastases by a Lewis Lung Carcinoma", <i>Cell</i> , 79:315-328 (1994) |
| | C13 | Teicher, B. A., <i>et al.</i> , "Antiangiogenic Agents Can Increase Tumor Oxygenation and Response to Radiation Therapy", <i>Radiation Oncology Investigations</i> , 2:269-276 (1995) |

EXAMINER

DATE CONSIDERED

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

(Form PTO-1449)

Form PTO - 1449 (Modified)

| | | |
|--|------------------------|------------|
| FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (Modified) PATENT AND TRADEMARK OFFICE | ATTY. DOCKET NO. | SERIAL NO. |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 CFR 1.98 (b)) | 5940.US.P2 | 08/851,350 |
| | APPLICANT | |
| | D. J. Davidson, et al. | |
| | FILING DATE | GROUP |
| | May 5, 1997 | |

U.S.PATENT DOCUMENTS

| EXAMINER INITIAL | | PATENT NUMBER | ISSUE DATE | PATENTEE | CLASS | SUB CLASS | FILING DATE |
|---------------------|--|---------------|---------------|----------|-------|--------------|----------------|
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

| | | DOCUMENT NUMBER | PUBLIC- ATION DATE | COUNTRY OR PATENT OFFICE | CLASS | SUB CLASS | TRANS- LATION |
|--|--|-----------------|--------------------------|-----------------------------|-------|--------------|------------------|
| | | | | | | | YES NO |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |

OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)

| | | |
|--|-----|--|
| | C14 | Teicher, B. A., et al., "Antiangiogenic Agents Potentiate Cytotoxic Cancer Therapies against Primary and Metastatic Disease", <i>Cancer Research</i> , 52:6702-6704 (1992) |
| | C15 | Teicher, B. A., et al., "Antiangiogenic Treatment (TNP-470/Minocycline) Increases Tissue Levels of Anticancer Drugs in Mice Bearing Lewis Lung Carcinoma", <i>Oncology Research</i> , 7(5):237-243 (1995) |
| | C16 | Teicher, B. A., et al., "β-Cyclodextrin tetradecasulfate/tetrahydrocortisol ± minocycline as modulators of cancer therapies in vitro and in vivo against primary and metastatic lewis lung carcinoma", <i>Cancer Chemother Pharmacol</i> , 33:229-239 (1993) |
| | C17 | Teicher, B. A., et al., "Influence of an Anti-Angiogenic Treatment on 9L Gliosarcoma: Oxygenation and Response to Cytotoxic Therapy", <i>Int. J. Cancer</i> , 61:732-737 (1995) |
| | C18 | Teicher, B. A., et al., "Potentiation of Cytotoxic Cancer Therapies by TNP-470 Alone and With Other Anti-Angiogenic Agents", <i>Int. J. Cancer</i> , 57:920-925 (1994) |
| | C19 | Teicher, B. A., et al., "Potentiation of cytotoxic therapies by TNP-470 and minocycline in mice bearing EMT-6 mammary carcinoma", <i>Breast Cancer Research and Treatment</i> , 36:227-236 (1995) |
| | C20 | Thewes, T., et al., "Isolation purification and 1H-NMR characterization of a kringle 5 domain fragment from human plasminogen", <i>Database Medline</i> , (1987) |
| | C21 | Thewes, T., et al., "Ligand Interactions with the Kringle 5 Domain of Plasminogen", <i>Journal of Biological Chemistry</i> , 265(7):3906-3915 (1990) |
| | C22 | Váradi, A., et al., "Kringle 5 of human plasminogen carries a benzamidine-binding site", <i>Biochemical and biophysical Research Communications</i> , 103:97-102 (1981) |
| | C23 | Weidner, N., et al., "Tumor Angiogenesis and Metastasis - Correlation in Invasive Breast Carcinoma", <i>The New England Journal of Medicine</i> , 324(1):1-8 (1991) |
| | | |

EXAMINER

DATE CONSIDERED

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.